Management ChangeJun 17, 2026, 05:31 PM
ProtoKinetix Appoints New President & Directors; Forms SightPath Biotech
AI Summary
ProtoKinetix, Inc. announced significant leadership changes, including the resignation of Edward McDonough and the appointment of Michael Jones, Jason Lamp, and Dr. Keith Brunt as directors. Dr. Brunt was also named president. The company formed SightPath Biotech LLC, a wholly-owned subsidiary, to develop its PKX-001 molecule for dry-eye disease, with related patents valued at approximately $253 million. Additionally, ProtoKinetix repriced 61.19 million stock options and 6 million warrants to an exercise price of $0.01 per share and extended their expiration dates. The company also noted late filings for its 2025 10-K and 2026 Q1 10-Q.
Key Highlights
- Edward McDonough resigned from the Board effective March 31, 2026.
- Michael Jones and Jason Lamp appointed as directors on June 17, 2026.
- Dr. Keith Brunt appointed director and president of the Company on June 17, 2026.
- Formed SightPath Biotech LLC on February 11, 2026, to develop PKX-001 for ocular diseases.
- Patents supporting dry-eye treatment valued at approximately $253 million.
- Filed late notifications for 2025 10-K and 2026 Q1 10-Q.
- Repriced 61.19 million stock options to $0.01, extended to December 6, 2030.
- Repriced 6 million warrants to $0.01, extended to December 12, 2030.
Price Impact